VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Novel target antigens to improve the efficacy of immunotherapeutics in multiple myeloma

Yu-Tzu Tai, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, comments on the complex interplay between tumor cells and immune cells in the bone marrow microenvironment of patients with multiple myeloma, highlighting promising immunotherapeutic target antigens that could be used in combination with existing or novel immunotherapeutics to overcome treatment resistance or improve anti-tumor immunity. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter